E

xpressing concerns about generic competition, a House committee asked Allergan (AGN) to provide a slew of documents about its controversial deal to sell patents on a best-selling drug to a Native American tribe.

In a letter sent on Tuesday to Allergan chief executive officer Brent Saunders, the Committee on Oversight and Government Reform wants the drug maker to cough up agreements, contracts, and analysis pertaining to the sale. An Allergan spokesman wrote us that the company intends to comply with the request.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X